Alvotech
NASDAQ:ALVODrug Manufacturers - Specialty & Generic
-$0.04 today
- Market cap
- $1.62B
- Beta
- 0.21
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.24
Volume 1.56M
Average 0.65M
ALVO Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
AlvotechNASDAQ: ALVO
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns negative
Q1 FY2026 other income / expenses was -$8.61M, compared with $82.84M a year earlier. Trailing-twelve-month other income / expenses was -$33.31M.
Context
- Other income / expenses amounted to 9.9% of revenue in FY2025, down 48.7 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$8.61M or moves back toward the trailing-twelve-month quarterly average of -$8.33M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 58.14M USD
- Year-over-year change
- +120.2%
- 4-year CAGR
- -9.4%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 58.14M | +120.2% |
| FY2024 | 2024-12-31 | (287.21M) | +3.0% |
| FY2023 | 2023-12-31 | (296.19M) | -44.3% |
| FY2022 | 2022-12-31 | (205.21M) | -337.9% |
| FY2021 | 2021-12-31 | 86.26M | — |
Other Income / Expenses vs competitors
How ALVO compares with its peers on the latest reported figures
- ALVO's LTM Mar 2026 other income / expenses of -$33.31M is the 4th highest of the 11 companies compared; the peer median is -$141.87M.
- Its year-over-year change of -20.6% is the 7th highest of 11, against a peer median of -9.9%.
- Other income / expenses amounts to 6.0% of revenue for ALVO, versus a peer median of 6.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.2B | +15.7% | — | 7.7% | |
| LTM Mar 2026 | -$3.53M | -58.3% | — | 4.1% | |
| LTM Mar 2026 | -$13.93M | +36.6% | — | 1.9% | |
| LTM Mar 2026 | -$33.31M | -20.6% | — | 6.0% | |
| LTM Mar 2026 | -$39.28M | -50.8% | — | 14.6% | |
| LTM Mar 2026 | -$81.68M | -6.0% | — | 10.3% | |
| LTM Jun 2026 | -$202.06M | +29.6% | — | 6.5% | |
| LTM Jun 2026 | -$415.9M | +31.7% | — | 4.2% | |
| LTM Sep 2026 | -$686M | -13.8% | — | 11.2% | |
| LTM Jun 2026 | -$1.26B | -31.0% | — | 7.3% | |
| LTM Jun 2026 | -$2.36B | -212.3% | — | 6.2% | |
| Peer median (excluding ALVO) | -$141.87M | -9.9% | — | 6.9% | |
Competitors are the stored peer set for ALVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 36.77M | 83.03M | 91.43M | 489.68M | 586.32M |
| Cost of Revenue | 0 | 64.1M | 160.86M | 185.31M | 235.56M |
| Gross Profit | 36.77M | 18.93M | (69.42M) | 304.37M | 350.76M |
| Gross Margin | 100.0% | 22.8% | -75.9% | 62.2% | 59.8% |
| Research & Development | 191.01M | 180.62M | 210.83M | 171.31M | 184.19M |
| Selling, General & Admin | 84.13M | 186.74M | 73.04M | 61.45M | 90.95M |
| Operating Expenses | 272.23M | 365.38M | 285.44M | 234.73M | 272.56M |
| Depreciation & Amortization | 18.2M | 20.41M | 24.21M | 31.3M | 37.85M |
| EBITDA | (18.03M) | (439.8M) | (493.67M) | (32.28M) | 323.39M |
| EBITDA Margin | -49.0% | -529.7% | -539.9% | -6.6% | 55.2% |
| Operating Income | (235.46M) | (346.44M) | (354.86M) | 69.64M | 78.21M |
| Operating Margin | -640.3% | -417.3% | -388.1% | 14.2% | 13.3% |
| Interest Income | 19K | 912K | 4.82M | 4.62M | 198.49M |
| Interest Expense | 112.97M | 91.44M | 134.82M | 157.6M | 149.19M |
| Other Income / Expenses | 86.26M | (205.21M) | (296.19M) | (287.21M) | 58.14M |
| Income Before Tax | (149.2M) | (551.65M) | (651.05M) | (217.56M) | 136.35M |
| Pre-Tax Margin | -405.7% | -664.4% | -712.0% | -44.4% | 23.3% |
| Income Tax Expense | (47.69M) | (38.07M) | (99.32M) | 14.3M | 108.43M |
| Net Income | (101.5M) | (513.58M) | (551.73M) | (231.86M) | 27.92M |
| Net Margin | -276.0% | -618.6% | -603.4% | -47.3% | 4.8% |
| EPS (Basic) | (3.25) | (2.60) | (2.43) | (0.87) | 0.10 |
| EPS (Diluted) | (3.25) | (2.60) | (2.43) | (0.87) | 0.10 |
| Weighted Avg Shares | 31.25M | 197.72M | 227.26M | 267.92M | 279.19M |
| Weighted Avg Shares (Diluted) | 31.25M | 197.72M | 227.26M | 267.92M | 279.19M |
Alvotech
NASDAQ:ALVO
Intrinsic Alpha fair value
Locked
Current Price
$4.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.